Yayın: Pharmacokinetics of pentoxifylline and its 5-hydroxyhexyl metabolite following intravenous administration in cattle
| dc.contributor.author | Uney, Kamil | |
| dc.contributor.author | Tras, Bunyamin | |
| dc.contributor.author | Corum, Orhan | |
| dc.contributor.author | Yildiz, Ramazan | |
| dc.contributor.author | Maden, Mehmet | |
| dc.date.accessioned | 2026-01-04T12:19:17Z | |
| dc.date.issued | 2018-09-15 | |
| dc.description.abstract | This study investigated the pharmacokinetics of pentoxifylline (PTX) and its 5-hydroxyhexyl metabolite (M-I) after single-dose intravenous (IV) administration (10 mg/kg) of PTX in six healthy cattle. The safety of PTX was evaluated by clinical observation and biochemical analysis. Plasma concentrations of PTX and M-I were simultaneously determined by reverse-phase high performance liquid chromatography. Pharmacokinetic parameters were calculated using non-compartmental methods. Salivation and discomfort were observed for 2 h following the drug administration. Serum direct bilirubin, total bilirubin, and phosphorus levels at 24 h following the drug administration were significantly different from the control values (0 h) (P < 0.05). Pharmacokinetic variables of PTX were characterized by a short terminal elimination half-life (1.05 ± 0.19 h), a large volume of distribution (6.30 ± 1.76 L/kg), and high total body clearance (5.31 ± 1.27 L/h/kg). The mean ratio between the area under the concentration-time curves of M-I and PTX was 1.34. These results indicate that single-dose administration of PTX at 10 mg/kg IV in cattle resulted in therapeutic concentrations similar to those observed in humans and horse. However, further studies are necessary to determine the safety and pharmacokinetics following repeated administrations of PTX. | |
| dc.description.uri | https://doi.org/10.1007/s11250-018-1710-8 | |
| dc.description.uri | https://pubmed.ncbi.nlm.nih.gov/30219998 | |
| dc.description.uri | https://dx.doi.org/10.1007/s11250-018-1710-8 | |
| dc.description.uri | https://hdl.handle.net/20.500.12395/38087 | |
| dc.identifier.doi | 10.1007/s11250-018-1710-8 | |
| dc.identifier.eissn | 1573-7438 | |
| dc.identifier.endpage | 441 | |
| dc.identifier.issn | 0049-4747 | |
| dc.identifier.openaire | doi_dedup___::f0c911e972a63e3edaec76770968855a | |
| dc.identifier.orcid | 0000-0002-8674-4873 | |
| dc.identifier.orcid | 0000-0003-3168-2510 | |
| dc.identifier.pubmed | 30219998 | |
| dc.identifier.scopus | 2-s2.0-85053618278 | |
| dc.identifier.startpage | 435 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12597/36968 | |
| dc.identifier.volume | 51 | |
| dc.identifier.wos | 000457396300021 | |
| dc.language.iso | eng | |
| dc.publisher | Springer Science and Business Media LLC | |
| dc.relation.ispartof | Tropical Animal Health and Production | |
| dc.rights | OPEN | |
| dc.subject | M-I metabolite | |
| dc.subject | Phosphodiesterase Inhibitors | |
| dc.subject | Area Under Curve | |
| dc.subject | Injections, Intravenous | |
| dc.subject | Animals | |
| dc.subject | Pharmacokinetics | |
| dc.subject | Administration, Intravenous | |
| dc.subject | Cattle | |
| dc.subject | Pentoxifylline | |
| dc.subject | Intravenous | |
| dc.subject | Chromatography, High Pressure Liquid | |
| dc.subject | Half-Life | |
| dc.subject.sdg | 2. Zero hunger | |
| dc.subject.sdg | 3. Good health | |
| dc.title | Pharmacokinetics of pentoxifylline and its 5-hydroxyhexyl metabolite following intravenous administration in cattle | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| local.api.response | {"authors":[{"fullName":"Uney, Kamil","name":"Kamil","surname":"Uney","rank":1,"pid":{"id":{"scheme":"orcid","value":"0000-0002-8674-4873"},"provenance":null}},{"fullName":"Tras, Bunyamin","name":"Bunyamin","surname":"Tras","rank":2,"pid":null},{"fullName":"Corum, Orhan","name":"Orhan","surname":"Corum","rank":3,"pid":{"id":{"scheme":"orcid","value":"0000-0003-3168-2510"},"provenance":null}},{"fullName":"Yildiz, Ramazan","name":"Ramazan","surname":"Yildiz","rank":4,"pid":null},{"fullName":"Maden, Mehmet","name":"Mehmet","surname":"Maden","rank":5,"pid":null}],"openAccessColor":null,"publiclyFunded":false,"type":"publication","language":{"code":"eng","label":"English"},"countries":null,"subjects":[{"subject":{"scheme":"FOS","value":"0301 basic medicine"},"provenance":null},{"subject":{"scheme":"SDG","value":"2. Zero hunger"},"provenance":null},{"subject":{"scheme":"keyword","value":"M-I metabolite"},"provenance":null},{"subject":{"scheme":"keyword","value":"Phosphodiesterase Inhibitors"},"provenance":null},{"subject":{"scheme":"FOS","value":"04 agricultural and veterinary sciences"},"provenance":null},{"subject":{"scheme":"SDG","value":"3. Good health"},"provenance":null},{"subject":{"scheme":"FOS","value":"0403 veterinary science"},"provenance":null},{"subject":{"scheme":"FOS","value":"03 medical and health sciences"},"provenance":null},{"subject":{"scheme":"keyword","value":"Area Under Curve"},"provenance":null},{"subject":{"scheme":"keyword","value":"Injections, Intravenous"},"provenance":null},{"subject":{"scheme":"keyword","value":"Animals"},"provenance":null},{"subject":{"scheme":"keyword","value":"Pharmacokinetics"},"provenance":null},{"subject":{"scheme":"keyword","value":"Administration, Intravenous"},"provenance":null},{"subject":{"scheme":"keyword","value":"Cattle"},"provenance":null},{"subject":{"scheme":"keyword","value":"Pentoxifylline"},"provenance":null},{"subject":{"scheme":"keyword","value":"Intravenous"},"provenance":null},{"subject":{"scheme":"keyword","value":"Chromatography, High Pressure Liquid"},"provenance":null},{"subject":{"scheme":"keyword","value":"Half-Life"},"provenance":null}],"mainTitle":"Pharmacokinetics of pentoxifylline and its 5-hydroxyhexyl metabolite following intravenous administration in cattle","subTitle":null,"descriptions":["This study investigated the pharmacokinetics of pentoxifylline (PTX) and its 5-hydroxyhexyl metabolite (M-I) after single-dose intravenous (IV) administration (10 mg/kg) of PTX in six healthy cattle. The safety of PTX was evaluated by clinical observation and biochemical analysis. Plasma concentrations of PTX and M-I were simultaneously determined by reverse-phase high performance liquid chromatography. Pharmacokinetic parameters were calculated using non-compartmental methods. Salivation and discomfort were observed for 2 h following the drug administration. Serum direct bilirubin, total bilirubin, and phosphorus levels at 24 h following the drug administration were significantly different from the control values (0 h) (P < 0.05). Pharmacokinetic variables of PTX were characterized by a short terminal elimination half-life (1.05 ± 0.19 h), a large volume of distribution (6.30 ± 1.76 L/kg), and high total body clearance (5.31 ± 1.27 L/h/kg). The mean ratio between the area under the concentration-time curves of M-I and PTX was 1.34. These results indicate that single-dose administration of PTX at 10 mg/kg IV in cattle resulted in therapeutic concentrations similar to those observed in humans and horse. However, further studies are necessary to determine the safety and pharmacokinetics following repeated administrations of PTX."],"publicationDate":"2018-09-15","publisher":"Springer Science and Business Media LLC","embargoEndDate":null,"sources":["Crossref"],"formats":["application/pdf"],"contributors":["Selcuk University Institutional Repository"],"coverages":null,"bestAccessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/"},"container":{"name":"Tropical Animal Health and Production","issnPrinted":"0049-4747","issnOnline":"1573-7438","issnLinking":null,"ep":"441","iss":null,"sp":"435","vol":"51","edition":null,"conferencePlace":null,"conferenceDate":null},"documentationUrls":null,"codeRepositoryUrl":null,"programmingLanguage":null,"contactPeople":null,"contactGroups":null,"tools":null,"size":null,"version":null,"geoLocations":null,"id":"doi_dedup___::f0c911e972a63e3edaec76770968855a","originalIds":["1710","10.1007/s11250-018-1710-8","50|doiboost____|f0c911e972a63e3edaec76770968855a","30219998","2891775662","oai:acikerisim.selcuk.edu.tr:20.500.12395/38087","50|od______4883::9266f753ea738524630c37039b562efd"],"pids":[{"scheme":"doi","value":"10.1007/s11250-018-1710-8"},{"scheme":"pmid","value":"30219998"},{"scheme":"handle","value":"20.500.12395/38087"}],"dateOfCollection":null,"lastUpdateTimeStamp":null,"indicators":{"citationImpact":{"citationCount":6,"influence":2.8088147e-9,"popularity":5.020029e-9,"impulse":1,"citationClass":"C5","influenceClass":"C5","impulseClass":"C5","popularityClass":"C4"}},"instances":[{"pids":[{"scheme":"doi","value":"10.1007/s11250-018-1710-8"}],"license":"Springer TDM","type":"Article","urls":["https://doi.org/10.1007/s11250-018-1710-8"],"publicationDate":"2018-09-15","refereed":"peerReviewed"},{"pids":[{"scheme":"pmid","value":"30219998"}],"alternateIdentifiers":[{"scheme":"doi","value":"10.1007/s11250-018-1710-8"}],"type":"Article","urls":["https://pubmed.ncbi.nlm.nih.gov/30219998"],"publicationDate":"2019-03-18","refereed":"nonPeerReviewed"},{"alternateIdentifiers":[{"scheme":"doi","value":"10.1007/s11250-018-1710-8"},{"scheme":"mag_id","value":"2891775662"}],"type":"Article","urls":["https://dx.doi.org/10.1007/s11250-018-1710-8"],"refereed":"nonPeerReviewed"},{"pids":[{"scheme":"handle","value":"20.500.12395/38087"}],"alternateIdentifiers":[{"scheme":"doi","value":"10.1007/s11250-018-1710-8"}],"type":"Article","urls":["https://doi.org/10.1007/s11250-018-1710-8","https://hdl.handle.net/20.500.12395/38087"],"publicationDate":"2019-01-01","refereed":"nonPeerReviewed"}],"isGreen":true,"isInDiamondJournal":false} | |
| local.import.source | OpenAire | |
| local.indexed.at | WOS | |
| local.indexed.at | Scopus | |
| local.indexed.at | PubMed |
